Highest-materiality recent filing
CRISPR Q2 CASGEVY revenue $76M (+151% YoY); FDA expands approval to children 2+
CASGEVY Q2 revenue $76M, up 78% QoQ and 151% YoY; FDA approved for children 2+ with SCD/TDT, adding ~5,500 eligible patients.
CRISPR Q1 2026: net loss narrows to $122.9M; CASGEVY revenue $43M; cash at $2.44B
Net loss of $122.9M vs $136.0M in Q1 2025; R&D spend $68.6M, G&A $17.2M.
CRISPR Therapeutics completes $600M convertible note offering due 2031
Issued $600M aggregate principal of Convertible Senior Notes due 2031; net proceeds ~$585.2M.
CRISPR Therapeutics prices $550M convertible notes due 2031 at 1.125% coupon
Aggregate principal amount upsized from $350M to $550M; net proceeds estimated at ~$536.3M.
CTX310 (ANGPTL3) advanced to Phase 1b for severe hypertriglyceridemia and refractory hypercholesterolemia after positive Phase 1 data.
Q3 net loss $106.4M vs $85.9M YoY; cash & equivalents $1.94B (flat vs Dec 2024).
CRISPR Therapeutics files $600M ATM offering through Jefferies
Filed prospectus supplement to sell up to $600M of common shares at-the-market.
Net loss of $208.5M in Q2 2025 vs $126.4M in Q2 2024; cash & securities $1.72B down from $1.90B at end-2024.
CRISPR Therapeutics reports up to 86% LDL reduction with CTX310; delays CTX320 data to H1 2026
CTX310 Phase 1 shows up to 82% TG and 86% LDL reductions at 0.8 mg/kg with stable liver enzymes.
CRISPR Therapeutics enters collaboration with Sirius on FXI-targeting siRNA; positive Phase 1 data
Upfront consideration: $70M in common shares + $25M cash to Sirius for co-development of FXI-targeting siRNA SRSD107.
CRISPR Therapeutics Q1 2025 net loss $136M; CTX310 Phase 1 shows up to 82% TG reduction
Net loss of $136.0M in Q1 2025, compared to $116.6M in Q1 2024; cash & equivalents $1.86B.
CRSP COO Julianne Bruno steps down effective April 11, 2025
Julianne Bruno resigns as COO of CRISPR Therapeutics to pursue external opportunities.
CRISPR Therapeutics Q4 net loss $37.3M; cash at $1.9B; 50+ ATCs activated
Q4 2024 net loss of $37.3M vs net income of $89.3M in Q4 2023.
CRISPR reports Q3 net loss $85.9M; CASGEVY now approved in Switzerland and Canada
Net loss $85.9M in Q3 2024 vs $112.2M loss in Q3 2023; cash and securities $1.935B as of Sept 30.
CRISPR Therapeutics Q2 2024 net loss widens to $126.4M; CASGEVY launch with 35+ ATCs
Net loss $126.4M vs $77.7M in Q2 2023; R&D expenses down to $80.2M from $101.6M.
Net loss of $116.6M in Q1 2024 vs $53.1M in Q1 2023; R&D expenses fell 24% to $76.2M.
CRISPR Therapeutics 2023: CASGEVY approved in 5 countries; Q4 net income $89.3M
CASGEVY (exa-cel) approved in U.S., EU, Great Britain, Bahrain, KSA for SCD and TDT; ~35,000 patients in U.S. and Europe.
European Commission granted conditional marketing authorization for CASGEVY (exa-cel).
CRISPR Therapeutics to raise ~$280M via sale of 3.9M common shares at $71.50/share
Issues 3,916,082 common shares at $71.50 per share to institutional investors.
FDA approves CRISPR's CASGEVY for transfusion-dependent beta thalassemia in patients 12+
U.S. FDA approved CASGEVY (exagamglogene autotemcel) on Jan 16, 2024 for transfusion-dependent beta thalassemia in patients 12 years and older.
CHMP positive opinion for CASGEVY conditional EU approval in sickle cell and beta thalassemia
EMA's CHMP adopted positive opinion for conditional approval of CASGEVY (exagamglogene autotemcel) for severe sickle cell disease and transfusion-dependent beta thalassemia.
CRISPR amends Vertex collaboration on exa-cel; $20M contingent payment, cost deferral adjustments
CRISPR agrees to pay Vertex $20M contingent payment upon specified event under Amendment No. 1 for exa-cel.
FDA approves first CRISPR therapy, CASGEVY; Vertex to pay CRSP $200M milestone
FDA approved CASGEVY (exagamglogene autotemcel) for sickle cell disease in patients 12+ with recurrent vaso-occlusive crises.
Next-generation candidates CTX112 (CD19) and CTX131 (CD70) incorporate knock-out of Regnase-1 and TGFBR2 to enhance potency.
CRISPR/VERTEX get UK conditional approval for CASGEVY in sickle cell & beta thalassemia
CASGEVY (exagamglogene autotemcel) received conditional marketing authorization from UK MHRA.
CRISPR Q3 net loss narrows; exa-cel PDUFA: Dec 8 (SCD) & Mar 30, 2024 (TDT)
PDUFA target action date for exa-cel in sickle cell disease: Dec 8, 2023; for beta thalassemia: March 30, 2024.
CRISPR Q2 2023 net loss $77.7M; FDA accepts exa-cel BLAs with PDUFA Dec 8 for SCD
FDA accepted BLAs for exa-cel: Priority Review for SCD (PDUFA Dec 8, 2023), Standard Review for TDT (Mar 30, 2024).
FDA accepts exa-cel BLAs; pivotal trials meet primary endpoints in SCD and TDT
FDA granted Priority Review for SCD (PDUFA Dec 8, 2023) and Standard Review for TDT (PDUFA Mar 30, 2024).
CRISPR Therapeutics reports Q1 net loss of $53.1M; exa-cel submissions complete in US, EU, UK
Revenue of $100.0M from Vertex upfront; net loss improved to $53.1M vs $179.2M in Q1 2022.
CRISPR and Vertex complete rolling BLA submission to FDA for exa-cel for SCD and TDT
Completed rolling Biologics License Applications for exa-cel for sickle cell disease and transfusion-dependent beta thalassemia.
CRISPR Therapeutics licenses CRISPR/Cas9 to Vertex for $100M upfront; eligible for $230M milestones
Vertex pays $100M upfront for non-exclusive rights to CRISPR/Cas9 for hypoimmune cell therapies in type 1 diabetes.
CRISPR Therapeutics appoints Raju Prasad as CFO, replaces Brendan Smith
Raju Prasad, Ph.D., appointed CFO effective March 14, 2023; previously Partner at William Blair.
Cash, cash equivalents and marketable securities were $1,868.4M as of Dec 31, 2022, down from $2,379.1M a year ago.
CRISPR Q3 net loss $174.5M; exa-cel rolling FDA review starts Nov, EMA/MHRA by year-end
CRISPR Q3 net loss $174.5M, cash $1.97B; R&D spend up to $116.6M.
CRISPR Therapeutics COO Lawrence Klein resigns; search for successor underway
COO Lawrence Klein, Ph.D., resigns effective Oct 27, 2022; will stay through year-end for transition.
FDA grants rolling review for CRISPR/Vertex exa-cel; submissions planned Q4 2022 / Q1 2023
FDA granted rolling review for exa-cel BLA for sickle cell disease and transfusion-dependent beta thalassemia.
CRISPR Q2 net loss $185.8M; exa-cel on track for EU/UK regulatory filing by year-end
Net loss of $185.8M in Q2 2022 vs net income of $759.2M in Q2 2021; revenue fell to $0.2M from $900.2M due to prior-year Vertex upfront.
Exa-cel shows 95% TDT transfusion-free; CTX130 achieves 70% ORR in T-cell lymphoma
42 of 44 TDT patients transfusion-free; all 31 SCD patients free of VOCs; follow-up up to 37.2 months.
On March 24, 2025, Julianne Bruno informed CRISPR Therapeutics AG (the “Company”) that she would be stepping down from the Company to pursue external opportunities, effective as of April 11, 2025, and she resigned from her position as Chief Operating Officer of the Company.
On May 23, 2024, CRISPR Therapeutics AG (the “Company”) announced the promotion of Julianne Bruno, currently the Company’s Senior Vice President and Head of Programs & Portfolio, to be the Company’s Chief Operating Officer effective as of May 23, 2024.
On December 14, 2023, Phuong Khanh Morrow, M.D., FACP resigned as Chief Medical Officer of CRISPR Therapeutics AG (the “Company”) to be effective as of January 26, 2024.
On September 7, 2023, CRISPR Therapeutics AG (the “Company”) announced that Rodger Novak, M.D. tendered his resignation as President of the Company as well as a director and Chairman of the Company’s Board of Directors (the “Board”), and all such resignations to be effective as of September 15, 2023 (the “Resignation Date”).
On March 28, 2023, Bradley Bolzon, Ph.D. notified the Board of Directors of CRISPR Therapeutics AG (the “Company”) of his intention to resign as a director of the Company, effective as of the close of business on March 28, 2023.
On March 13, 2023, CRISPR Therapeutics AG (the “Company”) announced the hiring and appointment of Raju Prasad, Ph.D. as its Chief Financial Officer, effective March 14, 2023.
On October 27, 2022, Lawrence O. Klein, Ph.D. resigned from his position as Chief Operating Officer of CRISPR Therapeutics AG.
On December 14, 2021, Tony W. Ho was terminated from his position as Executive Vice President, Research and Development of CRISPR Therapeutics AG (the “Company”).
On October 14, 2021, CRISPR Therapeutics AG (the “Company”) announced the hiring and appointment of Brendan Smith as its Senior Vice President and Chief Financial Officer, effective immediately.
Max materiality 0.90 · Median 0.70 · Most common event earnings